Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828763 · ClinicalTrials.gov registry record · Phase 1
GSK1349572 Mass Balance Study
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00828763: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT00828763 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00828763, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Mass balance study to determine the recovery of a single radiolabelled dose of GSK1349572 from urine and feces
Interventions
- DRUG [14c}-GSK1349572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
What the finished NCT00828763 record still lists
NCT00828763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [14c}-GSK1349572 is the first listed.
NCT00828763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00828763 about?
NCT00828763 is a clinical study titled "GSK1349572 Mass Balance Study". Mass balance study to determine the recovery of a single radiolabelled dose of GSK1349572 from urine and feces
What is the current status of trial NCT00828763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-02. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00828763?
The interventions under investigation include: [14c}-GSK1349572 (DRUG).
Who is sponsoring clinical trial NCT00828763?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00828763's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia